Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
215 studies found for:    Cerebral Atrophy
Show Display Options
Rank Status Study
21 Terminated
Has Results
Safety and Neuroprotective Effects of Polyphenon E in MS; Phase II
Condition: Multiple Sclerosis
Interventions: Drug: Polyphenon E;   Other: Placebo
22 Completed Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)
Conditions: Relapsing-Remitting Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis
Interventions: Drug: natalizumab;   Other: standard of care
23 Unknown  Gait and Alzheimer Interaction Tracking (GAIT) Study
Conditions: Gait Apraxia;   Alzheimer Disease;   Impaired Cognition;   Cerebral Atrophy
Intervention:
24 Unknown 
Has Results
A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: interferon beta-1a (Rebif®);   Biological: alemtuzumab
25 Recruiting Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD
Conditions: Atypical Alzheimers Disease;   Logopenic Variant of Primary Progressive Aphasia (LPA);   Posterior Cortical Atrophy (PCA)
Intervention: Drug: C-11 PiB
26 Completed Does Glaucoma Cause Loss of Brain Function?
Condition: Glaucoma
Intervention:
27 Completed Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Biological: intravenous injection of mesenchymal stem cells;   Biological: injection of cell free media
28 Active, not recruiting Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)
Condition: Multiple Sclerosis, Chronic Progressive
Interventions: Drug: lipoic acid;   Drug: Placebo
29 Terminated
Has Results
Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: Glatiramer Acetate;   Drug: Placebo;   Drug: Prednisone
30 Not yet recruiting MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial
Condition: Secondary Progressive Multiple Sclerosis
Interventions: Drug: Amiloride;   Drug: Riluzole;   Drug: Ibudilast;   Drug: Placebo
31 Not yet recruiting Automated Brain Morphometry for Dementia Diagnosis
Condition: Dementia
Interventions: Device: Brain Morphometry;   Other: Standard radiological assessment
32 Completed A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis
Condition: Secondary Progressive Multiple Sclerosis
Intervention: Drug: Lamotrigine
33 Completed Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b
Condition: Relapsing-remitting Multiple Sclerosis
Interventions: Drug: Interferon beta-1b group;   Drug: Interferon beta-1b/Atorvastatin group
34 Recruiting Study to Assess Safety and Efficacy of Fingolimod in Children With Rett Syndrome
Condition: Rett's Syndrome
Intervention: Drug: fingolimod (FTY720)
35 Unknown  Far Infrared Irradiation for the Management, Control and Treatment of Frontotemporal Dementia
Condition: Pick Disease of the Brain
Intervention: Radiation: Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
36 Unknown  The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention: Drug: lamotrigine
37 Terminated Flupirtine as Oral Treatment in Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: Flupirtine;   Drug: Placebo
38 Withdrawn Evaluation of Effects of Multiple Dose Regimens of CHF 5074 on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment
Condition: Alzheimer's Disease
Interventions: Drug: CHF 5074 1x;   Drug: CHF 5074 2x;   Drug: Placebo
39 Recruiting Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach
Condition: Multiple System Atrophy
Interventions: Drug: EGCG as putative neuroprotective agent;   Drug: Placebo
40 Recruiting Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)
Condition: Multiple Sclerosis
Intervention: Drug: Rituximab

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years